Top
Neoplasms of Bone and Articular Cartilage - Healing Genes
744
post-template-default,single,single-post,postid-744,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Neoplasms of Bone and Articular Cartilage

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Iovance Alliance: LN-145 Across Multiple Tumor Types

Clinical Study to Assess Efficacy and Safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types


Phase 2

DESCRIPTION:

Researchers at the University of Texas MD Anderson Cancer Center are recruiting patients with recurrent neoplasms of bone and articular cartilage or female genital organs to trial a combination treatment of routine chemotherapy and tumor-infiltrating lymphocytes (TILs) from the patient’s own body, collected and multiplied in the lab to magnify their ability to infiltrate and battle tumors.

The treatment will involve extraction of TILs from the patient’s tumor, then lab processing will amplify their numbers and optimize their anti-tumor potential. After a chemotherapy course, the TILs will be infused along with a pro-drug to help their growth. Observation and questionnaires will be required for the first 12 weeks, then follow up continues for ~2 years.


PATIENT MUST:

  • Be 16 to 70 years of age
  • Meet cancer screening requirements specific to the study
  • Not be pregnant or breastfeeding, be willing to use contraception for the study period
  • Not have active viral hepatitis

THE STUDY INVOLVES:

  1. Screening before the treatment.
  2. A course of chemotherapy prior to first Tetanus/Diptheria booster.
  3. Vaccine injections under the skin 22-24 days after step (2), then at 2 week intervals with recurring cycles of chemo until their disease shows progression or they experience toxicity.
  4. Monitoring of the patient during treatment, then follow up via lab and physical assessments for ~2 years.

LOCATIONS AND CONTACTS:

University of Texas MD Anderson Cancer Center in Houston, TX is recruiting participants for this study. Map

 

Contact: Ljiljana Milojevic  |  713-792-8578  |  [email protected]

Contact: Virginia A Bayer, RN  |  713-563-3877  |  [email protected]

 

SPONSOR INFORMATION:

University of Florida

National Cancer Institute (NCI)

 

Or go online:

https://clinicaltrials.gov/ct2/show/NCT03449108

 

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader